• US company Tezcat Biosciences produces encouraging Sofra results
• Unique delivery system to carry Noxopharm drugs to target sites
• Collaboration progressing to next stage

Noxopharm Limited (ASX:NOX) has announced initial results from a US company, Tezcat Biosciences, testing assets from the Sofra™ technology platform. Tezcat Biosciences is a specialist cancer-focused company developing a unique delivery system that transports drugs to specific diseased cells within the body, including immune cells and cancer cells. Noxopharm signed a Material Transfer Agreement with Tezcat in late 2024, and the American company has been evaluating the payload potential of Sofra oligonucleotides. Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes, principally by demonstrating that Noxopharm's oligos can be successfully attached to Tezcat's delivery system to create a novel drug candidate with strong anti-inflammatory activity. These studies reinforce the versatility of the Sofra technology and how it can be efficiently tailored for specific use cases and administered in multiple ways. Following these encouraging results, Noxopharm and Tezcat are further developing their relationship and planning additional and more complex studies in animal models. This is expected to take several months, and shareholders will be updated in due course. The collaboration with Tezcat broadens the range of potential disease indications for Sofra, including in the cancer space, and represents a valuable opportunity to demonstrate systemic delivery of Noxopharm's Sofra oligos.

Noxopharm and Tezcat Biosciences are further developing their relationship and planning additional and more complex studies in animal models, which is expected to take several months. Shareholders will be updated in due course.